Xiaofei Wang, Fei Li, Jing Li, Xiaoguang Huo, Jiubo Sun, Wenzhe Xu
Journal: Medicine 2025;104(7):e41556
PMID: 39960910
RATIONALE
Primary cardiac angiosarcoma is very rare with a poor prognosis, and there is no recognized guideline for its diagnosis and treatment. Currently, there is no standardized adjuvant chemotherapy regimen following radical surgery for cardiac angiosarcoma. To date, the literature lacks reports on the use of albumin-bound paclitaxel as an adjuvant chemotherapy agent in this context. This case report aims to document and evaluate the imaging characteristics of the disease and the efficacy of albumin-bound paclitaxel as adjuvant chemotherapy, thereby providing valuable insights for clinical diagnosis and treatment.
PATIENT CONCERNS
We report a 70-year-old patient with right atrial angiosarcoma, who presented with atrial fibrillation as the initial symptom.
DIAGNOSES
Transesophageal echocardiography, chest computed tomography, and cardiac magnetic resonance imaging showed a right atrial mass.
INTERVENTIONS
After radical resection, the patient was given 4 cycles of albumin-bound paclitaxel adjuvant chemotherapy.
OUTCOMES
Multiple metastases occurred in a short period of time, and the patient died 13 months after surgery. Surgical resection is the most important treatment for cardiac angiosarcoma, and the optimal adjuvant therapy needs to be further studied.
LESSONS
The limitation of this case report is its reliance on a single case, resulting in a limited sample size. To comprehensively characterize cardiac angiosarcoma and evaluate the efficacy of albumin-bound paclitaxel chemotherapy, future studies should collect additional cases and conduct long-term follow-up.
Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.